Shah Pritesh's Form 4 filing
NovoCure Ltd (NVCR) · filed Mar 2, 2023
- Accession no.
- 0001645113-23-000030
- Filed
- Mar 2, 2023
- Trade date
- Feb 28-Mar 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $146.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shah PriteshCIK 0001744884 | Officer (Chief Growth Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2023 | Ordinary Shares | AGrant or awardAcquired | +19,055 | $0.00 | $0 | 101,898 | Direct | |
| Mar 1, 2023 | Ordinary Shares | SSaleDisposed | −1,923 | $76.36 | −$146,840.28 | 99,975 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2023 | Ordinary Shares | AGrant or awardAcquired | +31,691 | $76.97 | +$2,439,256.27 | 31,691 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.